VALENCIA, SPAIN-(NewMediaWire - Jun 15, 2017) - Zenosense, Inc.
(OTC PINK: ZENO) ("Zenosense", the "Company"), a
healthcare technology company primarily focused on the development
and commercialization of MIDS Cardiac™, a Point of Care ("POC")
handheld device for the early detection of certain cardiac event
biomarkers to significantly accelerate the triage, diagnosis,
treatment and disposition of patients reporting chest pain and with
suspected acute myocardial infarction (heart attack), is pleased to
announce that its MIDS Medical Limited joint venture ("MML") based
at Sci-Tech, Daresbury (UK), has received notice of a patent
issuance in the U.S.
Our joint venture partner in MML has received a United States
Patent and Trademark Office grant for the issuance of the central
MIDS patent under number 9,678,064 in the U.S., namely:
"Immunoassay Apparatus Incorporating Microfluidic Channel".
This is as a result of a patent application originally filed in
2011 by our MML joint venture partner. It is one of a number of
applications made in commercially crucial regions for patent
protection of the central MIDS detection technology.
The same MIDS patent has already been granted in China. Other
applications have also successfully progressed into the national
phase in the EU and India. This issuance in the U.S. indicates that
these latter territories are also likely to progress to grant and,
if so, will establish intellectual property protection in these key
commercial regions. The MIDS patents are under license for the
exclusive use by MML and will be transferred directly to MML in the
event of the conclusion of a relevant commercial deal with a third
party.
Carlos Gil, CEO of Zenosense Inc.,
commented: "This latest grant of the MIDS patent in
the U.S. further validates our confidence in the ability of the MML
team to deliver this exciting technology. I also expect to be able
to provide a further update on development activities in the coming
weeks."
About Zenosense, Inc.
Zenosense Inc.'s primary focus, through our joint venture
ownership in MIDS Medical Ltd., is the development of a
cost-effective, hand-held Point of Care rapid cardiac diagnostic
device, MIDS Cardiac™, and is also the holder of an exclusive
global license agreement to develop and market effective medical
devices for use in hospitals and primary healthcare settings
targeting the early detection of both deadly bacteria and certain
cancers in the exhaled breath of patients.
To find out more about Zenosense (OTC PINK: ZENO), visit our website at www.zenosense.com.
Forward-Looking Statements
Statements in this news release that are not statements of
historical fact are forward-looking statements, which are subject
to certain risks and uncertainties. Forward-looking statements
can often be identified by words such as "expects," "intends,"
"plans," "may," "could," "should," "anticipates," "likely,"
"believes" and words of similar import. Forward-looking
statements are based on current facts and analyses and other
information that are based on forecasts of future results,
estimates of amounts not yet determined and assumptions of
management. Actual results may differ materially from those
expressed or implied by forward-looking statements due to a variety
of factors that may or may not be foreseeable or within the
reasonable control of the Company. Readers are cautioned not
to place undue reliance on such forward-looking
statements. Additional information on risks and other factors
that may affect the business and financial results of the Company
can be found in filings of the Company with the U.S. Securities and
Exchange Commission, including without limitation the section
entitled "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended December 31, 2016 filed on filed on April 17,
2017, and in Company reports filed subsequently
thereto. Except as otherwise required by law, the Company
disclaims any obligations or undertaking to publicly release any
updates or revisions to any forward-looking statement contained in
this news release to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based.
Respective statements concerning the development of both MIDS
Cardiac™ and other devices under development have been made based
on information obtained from MIDS Medical Ltd. and Zenon Biosystem,
which the Company believes to be accurate, but have not been
independently verified.